• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, October 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

OSU researcher expands research into deadly muscle-wasting syndrome

Bioengineer by Bioengineer
July 15, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

CORVALLIS, Ore. – An Oregon State University scientist has received a $2.3 million, five-year grant to build on his promising research into a debilitating muscle-wasting syndrome that kills as many as 30% of the cancer patients it afflicts.

Oleh Taratula of the OSU College of Pharmacy will use the award from the National Institutes of Health to lead an interdisciplinary team that includes Daniel Marks, a physician-scientist at Oregon Health & Sciences University. Marks specializes in treating the muscle-wasting syndrome, known as cachexia.

The researchers’ goal is to develop an effective treatment for cachexia based on nanoparticles loaded with messenger RNA. When the mRNA reaches the liver, it triggers the liver’s cellular machinery to produce a key protein, follistatin, that’s involved in building muscle mass.

In addition to cancers of the stomach, lungs and pancreas, cachexia is associated with many other chronic illnesses including multiple sclerosis, renal failure, cystic fibrosis, Crohn’s disease, rheumatoid arthritis and HIV.

People with cachexia will lose weight even if they eat, and not just fat but muscle mass as well.

Taratula, associate professor of pharmaceutical sciences, in 2018 published a paper that showed in a mouse model that the mRNA nanoplatform increased muscle mass while restricting fat accumulation.

In that study, mice were treated via subcutaneous injection – shots under the skin. The new research will aim to improve on the delivery of the nanoparticles to the liver by administering them intravenously, and studying their effectiveness in mice that have pancreatic or lung cancer.

“At the completion of the project, we hope to have strong evidence that the proposed therapy will preserve muscle mass and attenuate other features of cachexia in the mice we work with,” Taratula said. “The long-term impact will be doctors using therapy based on our work to significantly limit death and suffering among patients with various cancers.”

###

Media Contact
Oleh Taratula
[email protected]
https://beav.es/ZAm

Tags: cancerDiet/Body WeightGene TherapyGenesGeneticsMedicine/HealthNanotechnology/MicromachinesPharmaceutical ScienceTechnology/Engineering/Computer Science
Share12Tweet8Share2ShareShareShare2

Related Posts

Mini-Organs Uncover the Cervix’s Natural Defense Mechanisms

October 3, 2025

MCM2 Expression Predicts Type B Thymomas

October 3, 2025

MRI Radiomics Identifies Glioblastoma Survival Risks

October 3, 2025

Chidamide Boosts Lung Cancer Drug Sensitivity

October 3, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    93 shares
    Share 37 Tweet 23
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    88 shares
    Share 35 Tweet 22
  • Physicists Develop Visible Time Crystal for the First Time

    75 shares
    Share 30 Tweet 19
  • New Insights Suggest ALS May Be an Autoimmune Disease

    67 shares
    Share 27 Tweet 17

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Neonatal Encephalopathy: Advances in MRI and Spectroscopy

Encapsulated Pseudomonas Controls Pistachio Gummosis Effectively

Illuminating the Future: Transforming Streetlamps into Electric Vehicle Chargers

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 62 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.